TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28434760
Drug: n‐3 polyunsaturated
Approvals — FDA: no, EMA: no, PMDA: no
Description: n‐3 polyunsaturated fatty acids (PUFA) supplementation at a dosage of 1.28 g/day for 12 weeks
Study: 21402120
Drug: Mirtazapine (open
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mirtazapine (open label) for 6 weeks after initial treatment
Study: 20002596
Drug: Placebo (initial
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (initial treatment)
Study: 23120348
Drug: CT‐RT arm
Approvals — FDA: no, EMA: no, PMDA: no
Description: CT‐RT arm (neo‐adjuvant chemotherapy with Inj. Cisplatin 100 mg/m(2) on D(1) and Inj 5F.U. 700 mg/m(2) on D(1)‐D(4) at an interval of 21 days, followed by external radiation)
Study: 26265197
Drug: Topical diclofenac
Normalized name: diclofenac Topical Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical diclofenac epolamine 1.3% patch
Study: 26265197
Drug: Oral diclofenac
Normalized name: diclofenac Oral Solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diclofenac 50 mg
Study: 26265197
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium 50 mg
Study: 26265197
Drug: Diclofenac potassium
Normalized name: Diclofenac Potassium
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Diclofenac potassium plus ASA 325 mg
Study: 26265197
Drug: Diclofenac patch
Normalized name: diclofenac Medicated Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac patch plus aspirin
Study: 22366843
Drug: US-guided popliteal
Approvals — FDA: no, EMA: no, PMDA: no
Description: US-guided popliteal sciatic block (US-SPB) with 20 mL mepivacaine 1.5%
Study: 22366843
Drug: Nerve stimulator-guided
Normalized name: nerve growth factor
DrugBank: Nerve Growth Factor (DB12620)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nerve stimulator-guided popliteal sciatic block (NS-SPB) with 20 mL mepivacaine 1.5%
Study: 20060945
Drug: IC41 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC41 vaccine via subcutaneous (s.c.) or intradermal (i.d.) injections weekly (16 injections) or every other week (8 injections)
Study: 20060945
Drug: IC41 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC41 vaccine with imiquimod
Study: 20060945
Drug: IC41 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IC41 vaccine via intradermal injections
Study: 7607970
Drug: Radiation therapy
Normalized name: Sensitizers used in photodynamic/radiation therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiation therapy (RT) plus steroids
Study: 623119
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide (6 g daily, three times a day)
Study: 623119
Drug: Aluminum hydroxide
Normalized name: Aluminum Hydroxide
DrugBank: Aluminum hydroxide (DB06723)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aluminum hydroxide capsules
Study: 24352716
Drug: Bupropion (≤300
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupropion (≤300 mg/day)
Study: 24352716
Drug: SSRIs (sertraline,
Approvals — FDA: no, EMA: no, PMDA: no
Description: SSRIs (sertraline, paroxetine, or escitalopram)
Study: 12074777
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of 6g of L-arginine glutamate and 6 mg of yohimbine hydrochloride (AY)
Study: 12074777
Drug: 6 mg
Normalized name: boron 6 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 mg of yohimbine hydrochloride (YP)
Study: 6342395
Drug: Maternal magnesium
Normalized name: undecylenate
DrugBank: Undecylenic acid (DB11117)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Maternal magnesium sulfate infusion
Study: 31784875
Drug: Dimethyl fumarate
Normalized name: Dimethyl Fumarate
DrugBank: Dimethyl fumarate (DB08908)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Dimethyl fumarate (Tecfidera®), administered twice daily.
Study: 30193081
Drug: Pancreatic enzyme
Normalized name: Pancreatic enzyme
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancreatic enzyme replacement therapy (PERT) at maximum intake of 75,000 units per meal
Study: 30193081
Drug: No PERT
Approvals — FDA: no, EMA: no, PMDA: no
Description: No PERT treatment
Study: 19647382
Drug: BZA 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZA 20 mg/CE 0.625 mg
Study: 19647382
Drug: BZA 20
Approvals — FDA: no, EMA: no, PMDA: no
Description: BZA 20 mg/CE 0.45 mg
Study: 9345074
Drug: 9 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 9 weeks of induction chemotherapy (vincristine, doxorubicin, cyclophosphamide, prednisone) followed by 24 weeks of continuation chemotherapy (mercaptopurine, methotrexate) without radiotherapy
Study: 9345074
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of continuation chemotherapy after 9 weeks of induction chemotherapy
Study: 9345074
Drug: 24 weeks
Normalized name: deutetrabenazine
DrugBank: Deutetrabenazine (DB12161)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 24 weeks of continuation chemotherapy with radiotherapy after 9 weeks of induction chemotherapy
Study: 9345074
Drug: No further
Approvals — FDA: no, EMA: no, PMDA: no
Description: No further therapy after 9 weeks of induction chemotherapy
Study: 27484339
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.1 μg/kg/min)
Study: 27484339
Drug: Remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil infusion (0.1 μg/kg/min) + Alfentanil (5 μg/kg 10 min before end of surgery)
Study: 24762066
Drug: Anthracycline-based chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anthracycline-based chemotherapy followed by taxane therapy (Arm A)
Study: 24762066
Drug: Taxane therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane therapy followed by anthracycline-based chemotherapy (Arm B)
Study: 24762066
Drug: Chemotherapy sequence
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chemotherapy sequence (Arm A vs Arm B)
Study: 20205108
Drug: sulfonylurea plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sulfonylurea plus insulin
Study: 20205108
Drug: routine diet
Normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
Approvals — FDA: no, EMA: no, PMDA: no
Description: routine diet and sulfonylurea therapy
Study: 18580739
Drug: Back school
Normalized name: Pep-Back
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Back school program plus medication (n = 50)
Study: 18580739
Drug: Medication only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medication only (n = 52)
Study: 10072410
Drug: Clozapine (6.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clozapine (6.25 to 50 mg per day)
Study: 7793648
Drug: 0.2 mg
Normalized name: niacin 0.2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.2 mg oral clonidine
Study: 17294999
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg lidocaine
Study: 27578062
Drug: Focused history
Normalized name: AVOBENZONE 0.2 g in 1 g / BUTYLENE GLYCOL 0.1 g in 1 g TOPICAL CREAM [Focused Corrective]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Focused history in parallel choreography (concurrent with primary survey)
Study: 20009130
Drug: Interferon-ribavirin treatment
Normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Interferon-ribavirin treatment
Study: 15058117
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 mg/kg with rocuronium 0.6 mg/kg
Study: 15058117
Drug: Thiopentone 4
Normalized name: Thiopentone
DrugBank: Thiopental (DB00599)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Thiopentone 4 mg/kg with rocuronium 0.6 mg/kg
Study: 11302283
Drug: Low dose
Normalized name: Low Dose ASA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low dose diuretic (indapamide sustained release 1.5mg daily) and additional ACE inhibitor (perindopril) therapy if required
Study: 7979670
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (150 mg/day) for 7 days before operation
Study: 29875020
Drug: 0.5 ml
Normalized name: ethanol 0.5 ML/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 ml normal saline (BN group)
Study: 28319270
Drug: PFD patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: PFD patch
Study: 26044495
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (multi-component antenatal vaccine promotion package)
Study: 24350662
Drug: Oxybutynin patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxybutynin patch
Study: 11834153
Drug: Intensive care
Normalized name: Rapifen Intensive Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive care therapy (ICT) in neurosurgical intensive care unit for the first 2 weeks after admission
Study: 11834153
Drug: Conventional care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional care therapy (CCT) in ordinary ward
Study: 23796204
Drug: Cetuximab 250
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 250 mg/m²
Study: 23796204
Drug: Cetuximab 250
Normalized name: Cetuximab
DrugBank: Cetuximab (DB00002)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Cetuximab 250 mg/m² with paclitaxel 80 mg/m²
Study: 17699280
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor
Study: 9482764
Drug: OKG administration
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKG administration
Study: 26683756
Drug: Exenatide (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exenatide (5 mcg twice daily for 1 month, then 10 mcg twice daily for 2 months)
Study: 23031322
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin therapy (IIT) guided by real-time continuous glucose monitoring (CGM), n = 63
Study: 9239584
Drug: Etomidate (0.1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etomidate (0.1 mg/kg)
Study: 12399793
Drug: Midazolam (0.033
Approvals — FDA: no, EMA: no, PMDA: no
Description: Midazolam (0.033 mg/kg)
Study: 18678568
Drug: Functional thumb
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Functional thumb orthosis used daily
Study: 11054441
Drug: Paclitaxel 67.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 67.5 mg/m(2) and Carboplatin AUC 6 mg.min/mL
Study: 11054441
Drug: Paclitaxel 81
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Paclitaxel 81 mg/m(2) and Carboplatin AUC 6 mg/mL
Study: 11054441
Drug: Paclitaxel 54.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel 54.5 mg/m(2) to 94.5 mg/m(2)
Study: 9085389
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at points previously used for anti-smoking (test group, TG)
Study: 9085389
Drug: Acupuncture treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acupuncture treatment at points assumed to have no effect for smoking cessation (control group, CG)
Study: 3546149
Drug: Ofloxacin 200
Normalized name: ofloxacin 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 200 mg b.i.d. by oral route
Study: 3546149
Drug: Ofloxacin 400
Normalized name: ofloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ofloxacin 400 mg b.i.d. by oral route
Study: 23857248
Drug: Preladenant 10
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 10 mg BID for 5 days
Study: 23857248
Drug: Preladenant 100
Normalized name: Preladenant
DrugBank: Preladenant (DB11864)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Preladenant 100 mg BID for 5 days
Study: 23857248
Drug: Moxifloxacin 400
Normalized name: moxifloxacin 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxifloxacin 400 mg on day 5
Study: 18823310
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus strain GG (LGG) treatment
Study: 18823310
Drug: Lactobacillus rhamnosus
Normalized name: Lactobacillus Rhamnosus
DrugBank: Lacticaseibacillus rhamnosus (DB19282)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lactobacillus rhamnosus strain GG (LGG) treatment in adults
Study: 7577484
Drug: Pamidronate 90
Normalized name: pamidronate 90 mg intravenous powder for injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pamidronate 90 mg
Study: 12631257
Drug: Ibandronate 4
Normalized name: ibandronate
DrugBank: Ibandronate (DB00710)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibandronate 4 mg
Study: 3814226
Drug: 0.15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.15 mg/kg ketanserin
Study: 6340300
Drug: Placebo (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (10 ml saline)
Study: 24096438
Drug: Dinoprostone (10-mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dinoprostone (10-mg intra-vaginal insert)
Study: 12087347
Drug: Candesartan (single
Approvals — FDA: no, EMA: no, PMDA: no
Description: Candesartan (single dose) or vitamin C (coinfusion)
Study: 10689211
Drug: Once-daily cefdinir
Approvals — FDA: no, EMA: no, PMDA: no
Description: Once-daily cefdinir 600 mg
Study: 10689211
Drug: Twice-daily cefdinir
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily cefdinir 300 mg
Study: 10689211
Drug: Twice-daily cefuroxime
Normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Twice-daily cefuroxime axetil 250 mg
Study: 18981463
Drug: ABT-510 20
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-510 20 mg once a day
Study: 18981463
Drug: ABT-510 100
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: ABT-510 100 mg twice a day
Study: 12207594
Drug: Intravenous immunoglobulin
Normalized name: Intravenous immunoglobulin (IVIg)
DrugBank: Human immunoglobulin G (DB00028)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous immunoglobulin (IVIG) 2 g kg‐1, administered as an 8‐h infusion of 1 g kg‐1 daily for two consecutive days
Study: 12207594
Drug: Delayed treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed treatment with IVIG (control group)
Study: 2930745
Drug: Stamey endoscopic
Normalized name: Nelumbo nucifera stamen extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stamey endoscopic bladder neck suspension
Study: 1758315
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of seminar teaching and audiotapes
Study: 1758315
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of CAI and seminar teaching
Study: 31894026
Drug: Pemetrexed combined
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed combined with platinum drugs and evidence‐based nursing mode
Study: 31894026
Drug: Pemetrexed therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pemetrexed therapy and routine nursing mode
Study: 23665341
Drug: Adjuvanted vaccines
Normalized name: respiratory syncytial virus pre-fusion F protein
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adjuvanted vaccines (30 μg, 60 μg, 90 μg)
Study: 23665341
Drug: 30 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 30 μg adjuvanted formulation
Study: 9868662
Drug: Ceftriaxone 2
Normalized name: ceftriaxone 250 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxone 2 g once daily for 4 weeks
Study: 791194
Drug: 225 mg
Normalized name: tyrosine 225 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 225 mg maprotiline per day
Study: 791194
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg maprotiline per day (initial dosage for first 2 days)
Study: 30377712
Drug: L-arginine (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (9 g/day) for 6 weeks
Study: 28292574
Drug: Phospholipid liposomal
Normalized name: Egg Phospholipids
DrugBank: Egg phospholipids (DB14233)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phospholipid liposomal spray (Tears Again®)
Study: 16877734
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2 (day 1) every 21 days for four cycles
Study: 16877734
Drug: Vinorelbine 25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vinorelbine 25 mg/m2 (days 1 and 8) every 21 days for four cycles
Study: 9013263
Drug: Vitamin E
Normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin E 400 mg once a day orally for 4 weeks
Study: 9013263
Drug: Pre-treatment state
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment state
Study: 29759061
Drug: TAP block
Normalized name: Ivy Block
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAP block with 20 ml 0.375% ropivacaine
Study: 14675884
Drug: Simvastatin (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simvastatin (20 mg/day) + ACE inhibitor (lisinopril 5 mg/day)
Study: 14675884
Drug: ACE inhibitor
Normalized name: ACE INHIBITORS
Approvals — FDA: no, EMA: no, PMDA: no
Description: ACE inhibitor (lisinopril 5 mg/day) alone
Study: 10982926
Drug: Bioefficient Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bioefficient Therapy
Study: 1294745
Drug: Ibuprofen (analgesic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen (analgesic and antiinflammatory doses)
Study: 15504190
Drug: Dixyrazine 10
Normalized name: dixyrazine
DrugBank: Dixyrazine (DB13784)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dixyrazine 10 mg
Study: 9760006
Drug: Policosanol 5
Normalized name: policosanol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 5 mg twice daily
Study: 9760006
Drug: Policosanol 5
Normalized name: policosanol 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Policosanol 5 mg twice daily plus 125 mg aspirin
Study: 9760006
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus 125 mg aspirin
Study: 2455155
Drug: Metoprolol (MET),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (MET), 200 mg slow release (SR) q.d.
Study: 28679410
Drug: Moxibustion treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moxibustion treatment at CV8, CV12, LI4 and ST36, 30-min treatments twice a week for 8 weeks
Study: 21635753
Drug: Staircase recruitment
Normalized name: Humanized Bi-Specific Xmab(R) T Cell Recruiting Antibody Construct Directed Against Cd3 And Cd38
Approvals — FDA: no, EMA: no, PMDA: no
Description: Staircase recruitment manoeuvres (SRM) with decremental PEEP titration and targeted plateau pressure < 30 cm H2O
Study: 7901254
Drug: Aspirin plus
Normalized name: Aspirin Plus Antacid Extra Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin plus heparin followed by aspirin plus warfarin
Study: 14572753
Drug: Permixon (160
Approvals — FDA: no, EMA: no, PMDA: no
Description: Permixon (160 mg bid for three months)
Study: 14572753
Drug: Control (no
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (no treatment for 3 weeks before surgery)
Study: 10962896
Drug: Total mesorectal
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total mesorectal excision for middle and lower third rectal cancer
Study: 10962896
Drug: Multivisceral resections
Normalized name: alpha tocopherol / ascorbic acid / cholecalciferol / docosahexaenoic acid / docusate sodium / ferrous fumarate / folic acid / pyridoxine hydrochloride / tricalcium phosphate Oral Capsule [Nexa Select]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multivisceral resections for the treatment of advanced colorectal tumours
Study: 9380919
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of propofol administered i.v. immediately after fetal extraction
Study: 25362110
Drug: 160 mg
Normalized name: nadolol 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 160 mg of aspirin
Study: 31629656
Drug: Radiotherapy plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radiotherapy plus goserelin (10.8 mg subcutaneous injection on the first day of irradiation and 3 months later)
Study: 15201546
Drug: Amlodipine 5-10
Normalized name: amlodipine
DrugBank: Amlodipine (DB00381)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Amlodipine 5-10 mg
Study: 21974764
Drug: Valsartan 40-80
Normalized name: valsartan 80 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Valsartan 40-80 mg
Study: 11745199
Drug: Paclitaxel (135
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (135 mg/m2) over 24 hours with cisplatin (75 mg/m2) on a 21‐day cycle
Study: 11745199
Drug: Cisplatin (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (100 mg/m2) with gemcitabine (1 g/m2) on Days 1, 8, and 15 on a 28‐day cycle
Study: 11745199
Drug: Cisplatin (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin (75 mg/m2) with docetaxel (75 mg/m2) on a 21‐day cycle
Study: 11745199
Drug: Paclitaxel (225
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paclitaxel (225 mg/m2) over 3 hours with carboplatin (area under the curve, 6)
Study: 8323380
Drug: Intervention not
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention not specified, but involves treatment for rheumatoid arthritis with a focus on radiological progression.
Study: 28040448
Drug: Belladonna and
Normalized name: BELLADONNA AND DERIVATIVES, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belladonna and opium rectal suppositories (16.2/60 mg) administered rectally immediately after surgery and every 8 hours for a total of 3 doses.
Study: 28040448
Drug: Placebo suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories administered rectally immediately after surgery and every 8 hours for a total of 3 doses.
Study: 19756426
Drug: Placebo suppositories
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo suppositories
Study: 28040448
Drug: Belladonna and
Normalized name: BELLADONNA AND DERIVATIVES, PLAIN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Belladonna and opium rectal suppositories
Study: 25270958
Drug: Etanercept (0.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Etanercept (0.4 mg/kg twice weekly for 8 doses) plus systemic corticosteroids (2.0 mg/kg/day)
Study: 21285990
Drug: Dexamethasone, Aspirin,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone, Aspirin, and immediate addition of Diethylstilbestrol (DAiS)